{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T04:50:31Z","timestamp":1791521431278,"version":"4.3.4"},"reference-count":66,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The combination of immune checkpoint inhibitors (ICIs) with acetaminophen (APAP) and non-steroidal anti-inflammatory drugs (NSAIDs) is commonly employed in cancer treatment. However, potential drug\u2013drug interactions (DDIs) between these agents remain poorly understood. Our study aimed to identify interaction signals associated with the concomitant use of ICIs and APAP\/NSAIDs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data were obtained from the US FDA Adverse Event Reporting System (FAERS) covering the period from 1 January 2014, to 30 June 2025. Disproportionality analysis was conducted for data mining by calculating the reporting odds ratio and 95% confidence interval (95% CI). Adjusted RORs were analyzed using logistic regression, accounting for age, sex, and reporting year. Further confirmation was performed using both additive and multiplicative models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We identified 4,613 reports related to the combination of immune checkpoint inhibitors (ICIs) with acetaminophen (APAP) and non-steroidal anti-inflammatory drugs (NSAIDs). Significant interaction signals were observed for gastrointestinal disorders (adjusted ROR: 1.57, 95% CI: 1.41\u20131.70, additive model: 0.0549), investigations (adjusted ROR: 1.27, 95% CI: 1.13\u20131.43, additive model: 0.3847, multiplicative model: 1.3135), renal and urinary disorders (adjusted ROR: 4.68, 95% CI: 4.19\u20135.24, additive model: 3.5771, multiplicative model: 3.6312), and skin and subcutaneous tissue disorders (adjusted ROR: 1.64, 95% CI: 1.47\u20131.83, additive model: 0.6818, multiplicative model: 1.5996). Subset analysis revealed positive interaction signals for the combination of ICIs with APAP in gastrointestinal disorders and investigations, for all APAP\/NSAIDs combinations with ICIs in renal and urinary disorders, and for the combination of NSAIDs with ICIs in skin and subcutaneous tissue disorders.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Based on data from the FAERS, four systemic disorders were identified to be associated with drug\u2013drug interactions (DDIs) resulting from the combined use of ICIs and APAP\/NSAIDs. Further preclinical trials and well-designed, large-scale clinical studies are needed to explore the potential pharmacodynamic crosstalk, alterations in inflammatory pathway and changes in the tumor immune microenvironment induced by the co-administration of ICIs with APAP\/NSAIDs. This will help deepen the understanding of DDIs associated with this combination therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1833275","type":"journal-article","created":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T04:27:18Z","timestamp":1791520038000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Adverse reactions of immune checkpoint inhibitors combined with acetaminophen\/non-steroidal anti-inflammatory drugs (NSAIDs): a pharmacovigilance analysis of drug\u2013drug interactions"],"prefix":"10.3389","volume":"17","author":[{"given":"Xiayang","family":"Ren","sequence":"first","affiliation":[{"name":"Department of Pharmacy, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihui","family":"Xue","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Beijing Chaoyang District Sanhuan Cancer Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanfeng","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Comprehensive Oncology, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Xiangya Hospital, Central South University","place":["Changsha, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,9]]},"reference":[{"key":"B1","year":"2022"},{"key":"B2","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/j.annonc.2022.05.010","article-title":"Impact of acetaminophen on the efficacy of immunotherapy in cancer patients","volume":"33","author":"Bessede","year":"2022","journal-title":"Ann. Oncol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.critrevonc.2005.03.007","article-title":"Drug-drug interactions in oncology: why are they important and can they be minimized?","volume":"55","author":"Blower","year":"2005","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.immuni.2020.10.020","article-title":"Antagonistic inflammatory phenotypes dictate tumor fate and response to immune checkpoint blockade","volume":"53","author":"Bonavita","year":"2020","journal-title":"Immunity"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.cell.2018.01.004","article-title":"NK cells stimulate recruitment of cDC1 into the tumor microenvironment promoting cancer immune control","volume":"172","author":"B\u00f6ttcher","year":"2018","journal-title":"Cell"},{"key":"B6","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1007\/s40264-017-0564-8","article-title":"Muscular adverse drug reactions associated with proton pump inhibitors: a disproportionality analysis using the Italian national network of pharmacovigilance database","volume":"40","author":"Capogrosso Sansone","year":"2017","journal-title":"Drug Saf."},{"key":"B7","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1186\/gb-2004-5-9-241","article-title":"The cyclooxygenases","volume":"5","author":"Chandrasekharan","year":"2004","journal-title":"Genome Biol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"101703","DOI":"10.1016\/j.bpg.2020.101703","article-title":"Immunotherapy induced enterocolitis and gastritis - what to do and when?","author":"Cheung","year":"2020","journal-title":"Best. Pract. Res. Clin. Gastroenterol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1681\/ASN.2019070676","article-title":"Clinical features and outcomes of immune checkpoint inhibitor-associated AKI: a multicenter study","volume":"31","author":"Cortazar","year":"2020","journal-title":"J. Am. Soc. Nephrol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"e001361","DOI":"10.1136\/jitc-2020-001361","article-title":"Integrated analysis of concomitant medications and oncological outcomes from PD-1\/PD-L1 checkpoint inhibitors in clinical practice","volume":"8","author":"Cortellini","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"B11","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1111\/cup.12858","article-title":"Diverse types of dermatologic toxicities from immune checkpoint blockade therapy","volume":"44","author":"Curry","year":"2017","journal-title":"J. Cutan. Pathol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1080\/21645515.2016.1223001","article-title":"Effects of prophylactic ibuprofen and paracetamol administration on the immunogenicity and reactogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugated vaccine (PHiD-CV) co-administered with DTPa-combined vaccines in children: an open-label, randomized, controlled, non-inferiority trial","volume":"13","author":"Falup-Pecurariu","year":"2017","journal-title":"Hum. Vaccin Immunother."},{"key":"B13","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1097\/00001648-200109000-00018","article-title":"Relative risk of upper gastrointestinal complications among users of acetaminophen and nonsteroidal anti-inflammatory drugs","volume":"12","author":"Garc\u00eda Rodr\u00edguez","year":"2001","journal-title":"Epidemiology"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e003467","DOI":"10.1136\/jitc-2021-003467","article-title":"Acute kidney injury in patients treated with immune checkpoint inhibitors","volume":"9","author":"Gupta","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"B15","doi-asserted-by":"publisher","first-page":"iv264","DOI":"10.1093\/annonc\/mdy162","article-title":"ESMO guidelines committee. Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Haanen","year":"2018","journal-title":"Ann. Oncol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.kint.2024.09.017","article-title":"Diagnosis and management of immune checkpoint inhibitor-associated nephrotoxicity: a position statement from the American society of Onco-nephrology","volume":"107","author":"Herrmann","year":"2025","journal-title":"Kidney Int."},{"key":"B17","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1096\/fj.07-8506com","article-title":"Acetaminophen (Paracetamol) is a selective cyclooxygenase-2 inhibitor in man","volume":"22","author":"Hinz","year":"2008","journal-title":"FASEB J."},{"key":"B18","doi-asserted-by":"publisher","first-page":"31405","DOI":"10.1074\/jbc.M501489200","article-title":"Conversion of acetaminophen to the bioactive N-acylphenolamine AM404 via fatty acid amide hydrolase-dependent arachidonic acid conjugation in the nervous system","volume":"280","author":"H\u00f6gest\u00e4tt","year":"2005","journal-title":"J. Biol. Chem."},{"key":"B19","first-page":"11","article-title":"Paracetamol: mechanism of action, applications and safety concern","volume":"71","author":"J\u00f3\u017awiak-Bebenista","year":"2014","journal-title":"Acta Pol. Pharm."},{"key":"B20","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1111\/1759-7714.13845","article-title":"Effect of cyclooxygenase inhibitor use on immunotherapy efficacy in non-small cell lung cancer","volume":"12","author":"Kanai","year":"2021","journal-title":"Thorac. Cancer"},{"key":"B21","doi-asserted-by":"publisher","first-page":"30647","DOI":"10.1039\/d4ra04686b","article-title":"NSAIDs between past and present; a long journey towards an ideal COX-2 inhibitor lead","volume":"14","author":"Khalil","year":"2024","journal-title":"RSC Adv."},{"key":"B22","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.semcancer.2019.06.012","article-title":"Autoimmunity, checkpoint inhibitor therapy and immune-related adverse events: a review","volume":"64","author":"Khan","year":"2020","journal-title":"Semin. Cancer Biol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s40257-018-0384-3","article-title":"Toxic side effects of targeted therapies and immunotherapies affecting the skin, oral mucosa, hair, and nails","volume":"19","author":"Lacouture","year":"2018","journal-title":"Am. J. Clin. Dermatol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1002\/cpt.3721","article-title":"Comedications associated with immune-related adverse events from immune-checkpoint inhibitors","volume":"118","author":"Laurent","year":"2025","journal-title":"Clin. Pharmacol. Ther."},{"key":"B25","doi-asserted-by":"publisher","first-page":"e014360","DOI":"10.1136\/jitc-2025-014360","article-title":"Impact of NSAID type, initiation timing, duration and dose on clinical outcomes of immunotherapy in NSCLC: a multicenter two-cohort study","volume":"14","author":"Li","year":"2026","journal-title":"J. Immunother. Cancer"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1682686","DOI":"10.3389\/fimmu.2025.1682686","article-title":"Acetaminophen use and prognosis in cancer patients treated with immune checkpoint inhibitors: evidence from a meta-analysis","volume":"16","author":"Lin","year":"2025","journal-title":"Front. Immunol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1173952","DOI":"10.3389\/fimmu.2023.1173952","article-title":"Incidence and risk factors of acute kidney injury in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"14","author":"Liu","year":"2023","journal-title":"Front. Immunol."},{"key":"B28","unstructured":"Support documentation: MedDRA version 23"},{"key":"B29","doi-asserted-by":"publisher","first-page":"861723","DOI":"10.3389\/fimmu.2022.861723","article-title":"Effect of concomitant use of analgesics on prognosis in patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"13","author":"Mao","year":"2022","journal-title":"Front. Immunol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"e003024","DOI":"10.1136\/jitc-2021-003024","article-title":"Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies","volume":"10","author":"Michielin","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"B31","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1080\/00325481.2018.1429793","article-title":"Gastrointestinal safety and tolerability of oral non-aspirin over-the-counter analgesics","volume":"130","author":"Moore","year":"2018","journal-title":"Postgrad. Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.3389\/fphar.2019.01319","article-title":"Review of statistical methodologies for detecting drug-drug interactions using spontaneous reporting systems","volume":"10","author":"Noguchi","year":"2019","journal-title":"Front. Pharmacol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/s11095-020-02801-3","article-title":"Comparison of signal detection algorithms based on frequency statistical model for drug-drug interaction using spontaneous reporting systems","volume":"37","author":"Noguchi","year":"2020","journal-title":"Pharm. Res."},{"key":"B34","doi-asserted-by":"publisher","first-page":"bbab347","DOI":"10.1093\/bib\/bbab347","article-title":"Detection algorithms and attentive points of safety signal using spontaneous reporting systems as a clinical data source","volume":"22","author":"Noguchi","year":"2021","journal-title":"Brief. Bioinform"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1158\/0008-5472.CAN-16-2324","article-title":"Immune toxicities elicted by CTLA-4 blockade in cancer patients are associated with early diversification of the T-cell repertoire","volume":"77","author":"Oh","year":"2017","journal-title":"Cancer Res."},{"key":"B36","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1111\/fcp.12899","article-title":"Drug-drug interactions of protein kinase inhibitors in chronic myeloid leukaemia patients: a study using the French health insurance database","volume":"37","author":"Pajiep","year":"2023","journal-title":"Fundam. Clin. Pharmacol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.it.2019.04.002","article-title":"Adverse events following cancer immunotherapy: obstacles and opportunities","volume":"40","author":"Pauken","year":"2019","journal-title":"Trends Immunol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1681\/ASN.2018050488","article-title":"Nephrotoxicity of cancer immunotherapies: past, present and future","volume":"29","author":"Perazella","year":"2018","journal-title":"J. Am. Soc. Nephrol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1186\/s13046-022-02566-0","article-title":"T-cell repertoire diversity: friend or foe for protective antitumor response?","volume":"41","author":"Porciello","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"B40","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1046\/j.1365-2125.2000.00167.x","article-title":"Paracetamol, alcohol and the liver","volume":"49","author":"Prescott","year":"2000","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1016\/S0140-6736(09)61208-3","article-title":"Effect of prophylactic paracetamol administration at time of vaccination on febrile reactions and antibody responses in children: two open-label, randomised controlled trials","volume":"374","author":"Prymula","year":"2009","journal-title":"Lancet"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"B43","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.gastrohep.2023.10.009","article-title":"Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: position statement of the AEEH-AEG-SEPD-SEOM-GETECCU","volume":"47","author":"Riveiro-Barciela","year":"2024","journal-title":"Gastroenterol. Hepatol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"540","DOI":"10.3390\/vaccines10040540","article-title":"Exploring the mechanisms underlying the cardiotoxic effects of immune checkpoint inhibitor therapies","volume":"10","author":"Ronen","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"B45","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA adverse event reporting system","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int. J. Med. Sci."},{"key":"B46","doi-asserted-by":"publisher","first-page":"100373","DOI":"10.1016\/j.iotech.2023.100373","article-title":"TCR sequencing: applications in immuno-oncology research","volume":"17","author":"Sanrom\u00e1n","year":"2023","journal-title":"Immunooncol Technol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.2215\/CJN.00990119","article-title":"The incidence, causes, and risk factors of acute kidney injury in patients receiving immune checkpoint inhibitors","volume":"14","author":"Seethapathy","year":"2019","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41577-020-0275-8","article-title":"Dissecting the mechanisms of immune checkpoint therapy","volume":"20","author":"Sharma","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s40257-017-0336-3","article-title":"Dermatologic reactions to immune checkpoint inhibitors: skin toxicities and immunotherapy","volume":"19","author":"Sibaud","year":"2018","journal-title":"Am. J. Clin. Dermatol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"e995","DOI":"10.1097\/PR9.0000000000000995","article-title":"Nonopioid drug combinations for cancer pain: a systematic review","volume":"7","author":"Sohi","year":"2021","journal-title":"Pain Rep."},{"key":"B52","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/s41568-025-00890-z","article-title":"The impact of concomitant medications on treatment outcomes in patients with cancer receiving immune checkpoint inhibitors","volume":"26","author":"Stone","year":"2026","journal-title":"Nat. Rev. Cancer"},{"key":"B53","first-page":"123","article-title":"Cutaneous toxicities of immune checkpoint inhibitors: the role of the dermatologist","volume":"93","author":"Tattersall","year":"2020","journal-title":"Yale J. Biol. Med."},{"key":"B54","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1111\/j.1365-2125.2007.02900.x","article-title":"Detecting signals of drug-drug interactions in a spontaneous reports database","volume":"64","author":"Thakrar","year":"2007","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B55","unstructured":"FDA adverse event reporting system (FAERS) quarterly data extract files\n          \n          \n          2021"},{"key":"B56","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s002280000215","article-title":"Detecting drug-drug interactions using a database for spontaneous adverse drug reactions: an example with diuretics and non-steroidal anti-inflammatory drugs","volume":"56","author":"van Puijenbroek","year":"2000","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions","volume":"11","author":"van Puijenbroek","year":"2002","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B58","doi-asserted-by":"publisher","first-page":"560","DOI":"10.3978\/j.issn.2218-6751.2015.06.06","article-title":"Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities","volume":"4","author":"Villadolid","year":"2015","journal-title":"Transl. Lung Cancer Res."},{"key":"B59","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1136\/gut.2004.047100","article-title":"Prostaglandins and cancer","volume":"55","author":"Wang","year":"2006","journal-title":"Gut."},{"key":"B60","doi-asserted-by":"publisher","first-page":"e000889","DOI":"10.1136\/jitc-2020-000889","article-title":"Effect of cyclo-oxygenase inhibitor use during checkpoint blockade immunotherapy in patients with metastatic melanoma and non-small cell lung cancer","volume":"8","author":"Wang","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","article-title":"Fundamental mechanisms of immune checkpoint blockade therapy","volume":"8","author":"Wei","year":"2018","journal-title":"Cancer Discov."},{"key":"B62","doi-asserted-by":"publisher","first-page":"CD012637","DOI":"10.1002\/14651858.CD012637.pub2","article-title":"Oral paracetamol (acetaminophen) for cancer pain","volume":"7","author":"Wiffen","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1259628","DOI":"10.3389\/fphar.2023.1259628","article-title":"The association between aspirin use and immune-related adverse events in specific cancer patients receiving ICIs therapy: analysis of the FAERS database","volume":"14","author":"Yang","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1002\/pds.3626","article-title":"Acute kidney injury during concomitant use of valacyclovir and loxoprofen: detecting drug-drug interactions in a spontaneous reporting system","volume":"23","author":"Yue","year":"2014","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1016\/j.cell.2015.08.015","article-title":"Cyclooxygenase-dependent tumor growth through evasion of immunity","volume":"162","author":"Zelenay","year":"2015","journal-title":"Cell"},{"key":"B66","doi-asserted-by":"publisher","first-page":"1957605","DOI":"10.1080\/2162402X.2021.1957605","article-title":"The effect of concomitant use of statins, NSAIDs, low-dose aspirin, metformin and beta-blockers on outcomes in patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"10","author":"Zhang","year":"2021","journal-title":"Oncoimmunology"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1833275\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T04:27:21Z","timestamp":1791520041000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1833275\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,9]]},"references-count":66,"alternative-id":["10.3389\/fphar.2026.1833275"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1833275","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,9]]},"article-number":"1833275"}}